Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
Programmed Cell Death 4 inhibits breast cancer cell invasion by increasing Tissue Inhibitor of Metalloproteinases-2 expression
Src inhibitors in early breast cancer
Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence
Transcriptional profiles of progestogen effects in the postmenopausal breast
The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology
Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
Detection and downregulation of type IIGF receptor expression by antibody-conjugated quantum dots in breast cancer cells
Molecular profiles of progesterone receptor loss in human breast tumors
Axillary recurrence after negative sentinel lymph node biopsy
Pulsed reduced dose-rate radiotherapy
Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence
Association of genetic polymorphisms of ER-α and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women
Breast cancer characteristics at diagnosis and survival among Arab–American women compared to European– and African–American women
Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population
Changes in quality of life among breast cancer patients three years post-diagnosis
HER2 codon 655 polymorphism and breast cancer risk
Effect of Coenzyme Q10, Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles
Poor usage of HUGO standard gene nomenclature in breast cancer studies
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model